Epigenetic Mechanisms Mediating Resistance to Immunotherapy in Adrenocortical Carcinoma
Abstract
Adrenal Cancer (ACC) is a rare and aggressive tumor that originates in the adrenal gland. While there are currently no curative treatments for advanced ACC, immune therapy may ultimately prove effective, as it has for other cancers. Immune therapy is a type of cancer treatment that boosts the body s natural immune defenses to help fight cancer. It uses substances made by the body or in a laboratory to improve how the immune system works to find and kill cancer cells. Immunotherapy has shown encouraging efficacy in the treatment of a wide range of cancers. Unfortunately, early clinical trials of immune therapy in patients with ACC have shown poor treatment responses. What causes this remains unclear. The goal of this proposal is to use a new mouse model of ACC to discovery mechanisms that block immune therapy form working in patients with ACC. Focus Area: Biology and Etiology What types of patients will it help and how will it help them? This research will benefit patients with advanced forms of ACC who currently do not respond to immune therapy. What are the potential clinical applications, benefits, and risks? This research may lead to the discovery of new ways that ACC, and also other cancers, avoid detection by the immune system. Understanding these mechanisms may lead to new treatments for patients with ACC and other tumors that currently do not respond to immune therapy. What is the projected time anticipated to achieve a clinically relevant outcome? These studies could lead to new treatments for cancer within 5-10 years. What are the likely contributions of this study to advancing rare cancers research? This study is likely to lead to the discovery of new mechanisms that allow cancers to avoid the immune system.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252310726
Entities
People
- Kleiton Borges
Organizations
- United States Army